Targeting Val2: The Potential of Small Molecules for The Treatment of NFYA-related Diseases

Target Name: NFYA

NCBI ID: G4800

NFYA

Targeting Val2: The Potential of Small Molecules for The Treatment of NFYA-related Diseases

Nuclear transcription factor Y (NFYA) is a key regulator of gene expression and has been involved in various cellular processes, including cell growth, differentiation, and response to stimuli. The NFYA gene has four splice variants, two of which have been identified as transcript variants, Ala2 and Val2. Although both Ala2 and Val2 variants have been shown to function in cell-cycle regulation, recent studies have suggested that Val2 may have additional functions in the regulation of gene expression.

NFYA plays a crucial role in the regulation of gene expression by binding to specific DNA sequences. The protein encoded by the NFYA gene consists of a 176 amino acid long alpha subunit and a 14 amino acid long beta subunit. The alpha subunit contains the key regulatory functions of NFYA, including DNA binding, while the beta subunit is responsible for the protein's stability and localization to the nuclear matrix.

The Val2 variant has been shown to play a unique role in the regulation of gene expression in various cellular processes. Val2 has been shown to interact with histone modifications, such as histone H3 lysine 27 (H3K27me3), which are important for the regulation of gene expression. Additionally, Val2 has been shown to interact with the protein Scl/Nop, which is involved in the regulation of nuclear transport and has been implicated in the regulation of gene expression.

In addition to its role in the regulation of gene expression, Val2 has also been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and invasion. Val2 has been shown to interact with the protein F-actin, which is involved in the regulation of actin dynamics and has been implicated in the regulation of cell movement.

Given its involvement in the regulation of gene expression and cellular processes, the Val2 variant of NFYA has potential as a drug target or biomarker. The development of small molecules that can specifically target the Val2 variant of NFYA may provide new therapeutic options for the treatment of various diseases.

Targeting Val2

Several small molecules have been shown to interact with the Val2 variant of NFYA. One of the most promising compounds is a small molecule called valdecanilide, which is a inhibitor of Val2-dependent nuclear factor of transcriptional repression (NFR-Y). Valdecanilide has been shown to reduce the amount of Val2 in the nuclear matrix, which would lead to reduced binding of NFYA to DNA and reduce the level of gene expression.

Another small molecule that has been shown to interact with Val2 is the drug sunitinib, which is a selective inhibitor of the tyrosine kinase inhibitor (TKI) domain. Sunitinib has been shown to reduce the amount of Val2 in the nuclear matrix and to inhibit the recruitment of NFYA to DNA.

In addition to these small molecules, several other compounds have also been shown to interact with the Val2 variant of NFYA. However, further studies are needed to fully understand the effects of these compounds on the regulation of gene expression and the regulation of cellular processes.

Conclusion

The Val2 variant of the nuclear transcription factor Y (NFYA) has been shown to play a unique role in the regulation of gene expression and cellular processes. The Val2 variant has been shown to interact with histone modifications and other proteins, which may have implications for its function in the regulation of gene expression. The development of small molecules that can specifically target the Val2 variant of NFYA may provide new therapeutic options for the treatment of various diseases. Further studies are needed to fully understand the effects of these compounds on the regulation of gene expression and cellular processes.

Protein Name: Nuclear Transcription Factor Y Subunit Alpha

Functions: Component of the sequence-specific heterotrimeric transcription factor (NF-Y) which specifically recognizes a 5'-CCAAT-3' box motif found in the promoters of its target genes. NF-Y can function as both an activator and a repressor, depending on its interacting cofactors. NF-YA positively regulates the transcription of the core clock component BMAL1

The "NFYA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFYA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets